FcγR interaction is not required for effective anti‐PD‐L1 immunotherapy but can add additional benefit depending on the tumor model
暂无分享,去创建一个
G. Vidarsson | F. Ossendorp | C. Breukel | J. Verbeek | T. van Hall | A. Bentlage | H. Benonisson | Heng Sheng Sow | J. Claassens | C. Brouwers | M. Linssen | M. Fransen | R. Visser | M. Camps | O. Verhagen | J. Verbeek